BMS Enters A Catalyst-Rich Era Full Of Both LOEs And New Launches
2025-2030 Could Bring 10 NMEs, 30 Added Indications
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.
